Dexcom Inc (DXCM) concluded trading on Thursday at a closing price of $75.11, with 3.59 million shares of worth about $269.51 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 8.95% during that period and on March 20, 2025 the price saw a gain of about 2.36%. Currently the company’s common shares owned by public are about 390.70M shares, out of which, 385.25M shares are available for trading.
Stock saw a price change of 9.68% in past 5 days and over the past one month there was a price change of -16.25%. Year-to-date (YTD), DXCM shares are showing a performance of -3.42% which decreased to -44.25% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $62.34 but also hit the highest price of $142.00 during that period. The average intraday trading volume for Dexcom Inc shares is 3.81 million. The stock is currently trading -5.11% below its 20-day simple moving average (SMA20), while that difference is down -9.65% for SMA50 and it goes to -9.39% lower than SMA200.
Dexcom Inc (NASDAQ: DXCM) currently have 390.70M outstanding shares and institutions hold larger chunk of about 92.84% of that.
The stock has a current market capitalization of $29.35B and its 3Y-monthly beta is at 1.48. PE ratio of stock for trailing 12 months is 52.72, while it has posted earnings per share of $1.42 in the same period. Its PEG reads 2.33 and has Quick Ratio of 1.28 while making debt-to-equity ratio of 1.23. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DXCM, volatility over the week remained 3.67% while standing at 3.62% over the month.
Stock’s fiscal year EPS is expected to rise by 23.15% while it is estimated to increase by 22.53% in next year. EPS is likely to shrink at an annualized rate of 22.63% for next 5-years, compared to annual growth of 39.06% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Redburn Atlantic on February 03, 2025 offering a Buy rating for the stock and assigned a target price range of between $85 and $115 to it. Coverage by Robert W. Baird stated Dexcom Inc (DXCM) stock as an Outperform in their note to investors on January 16, 2025, suggesting a price target of $104 for the stock. On July 26, 2024, Robert W. Baird Downgrade their recommendations, while on July 26, 2024, JP Morgan Downgrade their ratings for the stock with a price target of $75. Stock get a Neutral rating from Redburn Atlantic on May 30, 2024.
